ADX71149
Epilepsy
Phase 2Active (Partner-led)
Key Facts
About Addex Therapeutics
Addex Therapeutics leverages its proprietary allosteric modulation platform to develop novel therapeutics for neurological and psychiatric disorders. The company's most advanced candidate, dipraglurant, is in Phase 2/3 development for Parkinson's disease dyskinesia, representing a significant unmet medical need. Addex is publicly traded on the SIX Swiss Exchange and Nasdaq, maintaining a focused pipeline with strategic partnerships to advance its research. Their approach aims to create drugs with improved selectivity and fewer side effects compared to traditional orthosteric compounds.
View full company profileTherapeutic Areas
Other Epilepsy Drugs
| Drug | Company | Phase |
|---|---|---|
| Soticlestat (TAK-935) | Takeda Pharmaceutical | Phase 3 |
| UCB4144 | UCB | Phase 2 |
| Keppra (levetiracetam) | UCB | Approved |
| NBI-921352 | Neurocrine Biosciences | Phase 2 |
| Oxtellar XR® | Supernus Pharmaceuticals | Approved/Commercial |
| Motpoly XR™ | Aucta Pharmaceuticals | Not Specified (Likely Phase 3/NDA) |
| ADB-104 | Adolore BioTherapeutics | Pre-clinical |